The FDA has mandated that Novavax conduct an additional clinical trial for its COVID-19 vaccine as part of the approval process for a new formulation targeting an updated variant. Novavax responded to the regulatory request in a standard manner, declining to comment further on the matter.

Novavax disclosed spending $170,000 on lobbying in Q1 2025 as per a new Lobbying Disclosure Act filing. The lobbying efforts focused on issues related to COVID-19 vaccine reauthorization, pandemic preparedness, and vaccine policy, raising concerns over corporate political influence in public health policy decisions.

On April 28, 2025, the FDA mandated that Novavax conduct a new clinical trial for its Covid vaccine as part of its approval process. Novavax confirmed that it had responded to an earlier FDA request for additional data—a procedure described as standard in the industry—without engaging in ad hoc political maneuvers.

According to OpenSecrets data, Novavax reported campaign finance totals for the current election cycle with $16,022 in contributions and $410,000 in lobbying expenditures in 2024. The figures were released by the FEC on February 06, 2025 and by the Senate Office of Public Records on February 19, 2025.

Novavax disclosed that it spent $100,000 on lobbying efforts during Q4 2024 on issues related to COVID-19 vaccine reauthorization and related legislative measures, as reported in a Nasdaq article.

Novavax Inc spent $470,000 on lobbying during the 2023 political cycle, as documented by OpenSecrets. This expenditure reflects the company's efforts to influence policy decisions.

Novavax released its Human Rights Policy outlining its commitment to adhere to international human rights standards, including the Universal Declaration of Human Rights and the UN Guiding Principles. The policy underscores the company's intent to promote ethical labor practices and safeguard human rights throughout its operations and supply chains.

Novavax has announced that, in compliance with the UK Modern Slavery Act, it is establishing new internal standards, procedures, and systems to improve due diligence around human trafficking, slavery, and illegal child labor in its supply chain. These measures, scheduled for implementation in Q3 2023, also include accountability protocols for employees and contractors failing to meet these standards.

Novavax published its UK Modern Slavery Act Statement outlining measures to prevent modern slavery within its supply chain, including due diligence procedures, regular supplier reviews, employee training, and enhanced internal accountability systems. The statement reaffirms its commitment to ethical business practices and protecting human rights.

In an SEC filing exhibit dated 22 October 2020, Novavax committed to implementing due diligence procedures in its supply chain. The company will verify that no slavery or human trafficking exists among its subcontractors before contracting with them, reinforcing its commitment to ethical business practices.